View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Strategy Research ... (+2)
  • ABGSC Strategy Research
  • Christer Linde
 PRESS RELEASE

Share buy-back program

Share buy-back program COMPANY ANNOUNCEMENT NO 61/2025 - December 15, 2025 On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction v...

 PRESS RELEASE

Transactions in connection with share buyback programme

Transactions in connection with share buyback programme Company Announcement Copenhagen, 15 December 2025No. 68/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, al...

 PRESS RELEASE

Genmab Announces Completion of Tender Offer for Outstanding Common Sha...

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidia...

 PRESS RELEASE

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 11, 2025 –  (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click . An archive of the webcast will be available on Genmab’s website. This meeting is not an official program of the ASH Annual Meeting. About Genmab Genmab i...

 PRESS RELEASE

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting P...

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential...

 PRESS RELEASE

Share buy-back program

Share buy-back program Share buy-back program On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction value of the share buy-backs ...

 PRESS RELEASE

Transactions in connection with share buyback programme

Transactions in connection with share buyback programme Company Announcement Copenhagen, 8 December 2025No. 67/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, als...

 PRESS RELEASE

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstra...

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R2 aloneEPKINLY + R2 was recently approved by the U.S. F...

 PRESS RELEASE

Genmab Announces Data From Multiple Clinical Trials Showing Treatment ...

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLB...

 PRESS RELEASE

Genmab Announces Closing of Private Offering of Senior Secured Notes a...

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offe...

 PRESS RELEASE

Transactions With Shares and Linked Securities in Genmab A/S Made by M...

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 1, 2025 – (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their beh...

 PRESS RELEASE

Share buy-back program

Share buy-back program COMPANY ANNOUNCEMENT NO 59/2025 - December 1, 2025 On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction va...

 PRESS RELEASE

Transactions in connection with share buyback programme

Transactions in connection with share buyback programme Company Announcement Copenhagen, 1 December 2025No. 66/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, als...

 PRESS RELEASE

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare...

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami Media ReleaseCOPENHAGEN, Denmark; November 24, 2025 (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare Conference in Miami at 9:45 AM EST (3:45 PM CET) on December 4, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients w...

 PRESS RELEASE

Share buy-back program

Share buy-back program COMPANY ANNOUNCEMENT NO 58/2025 - November 24, 2025 On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction v...

 PRESS RELEASE

Transactions in connection with share buyback programme

Transactions in connection with share buyback programme Company Announcement Copenhagen, 24 November 2025No. 65/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, al...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch